Project Grant R01DK139472
Award Date
1/1/25
Completion Date
12/31/29
Dollars Obligated
$714K
Federal Grant Program
93.847
Assistance Type
Project Grant
Place of Performance
Palo Alto, CA 94304, USA
Similar Awards
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a 5-year, $823,473 Cooperative Agreement (CFDA 93.847 Diabetes, Digestive, and Kidney Diseases Extramural Research) to The General Hospital Corporation (Massachusetts General Hospital) to characterize more homogenous subtypes of prediabetes and type 2 diabetes using multi-omic data, identify associations with complications, and develop new diagnostic tools. Key sub-awardees include Beth Israel Deaconess...
This federal Project Grant award, valued at $772,383, was provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The research project is dedicated to developing and optimizing non-peptide ligands designed to activate insulin receptors, with the goal of transforming approaches to glycemic control in diabetes management. The innovative strategy involves targeting...
This federal Project Grant award of $689,177 was provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The award aims to uncover the relationships between environmental, genetic, and 'omic factors in the development of type 2 diabetes (T2D). Key activities include: 1) Developing software to identify exposome-wide and genome-wide predictors of insulin resistance,...
This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), supports the development of a metabolomics-based laboratory test to better predict and monitor the progression of Type 1 Diabetes (T1D). The prime awardee, Metabolon, Inc., a leading provider of metabolomics solutions, will leverage its proprietary UHPLC-MS/MS platform to analyze metabolic...
This U01 Cooperative Agreement award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under CFDA 93.847 Diabetes, Digestive, and Kidney Diseases Extramural Research, provides $784,636 to The General Hospital Corporation (Massachusetts General Hospital) to develop new subtypes of type 2 diabetes and assess their clinical utility. The key objectives are to: 1) use machine learning to integrate multi-omic data and define new diabetes subtypes, 2) evaluate the...
This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under CFDA 93.847 Diabetes, Digestive, and Kidney Diseases Extramural Research program provides $583,732 in funding to Emory University from January 6, 2025 through December 31, 2029. The project aims to investigate the genetic and metabolomic factors associated with Type 2 Diabetes (T2D) and prediabetes phenotypes, particularly in the South Asian population, which exhibits unique...
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $526,902 Project Grant (CFDA 93.847 - Diabetes, Digestive, and Kidney Diseases Extramural Research) to the University of California, Los Angeles (UCLA) to deliver novel statistical methods, computational algorithms, and user-friendly software to study individual health trajectories relevant to disease onset and progression for large, complex biobank and electronic health record data. This work aims to push...
This $885,771 Project Grant was awarded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The grant recipient, Metanoia Bio Inc., will develop new pharmaceutical composition entities (NCEs) that inhibit the PFKFB3 enzyme. This approach aims to restore cell fitness competition, thereby triggering functional regeneration of pancreatic beta cells in type 2 diabetes....
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $800,000 Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to Beth Israel Deaconess Medical Center, Inc. (Bidmc) to support research on high-dimensional chemical targeting of multiple neuron types to regulate energy balance. The research aims to develop novel drug therapies that can jointly activate or inhibit specific transcriptional subtypes of AgRP...
This federal Project Grant award for $746,198, awarded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under CFDA Program 93.847 "Diabetes, Digestive, and Kidney Diseases Extramural Research", will fund a multi-omic study examining the relationship between exposure to per- and polyfluoroalkyl substances (PFAS) and the development of diabetic kidney disease (DKD) in youth with type 2 diabetes. The study, titled "PFAS Exposure and Diabetic Kidney...